Filing Details

Accession Number:
0000899243-16-013610
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-17 18:47:20
Reporting Period:
2016-02-17
Filing Date:
2016-02-17
Accepted Time:
2016-02-17 18:47:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1445283 Proteostasis Therapeutics Inc. PTI Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1114448 Ag Novartis Lichtstrasse 35
Basel V8 4056
No No Yes No
1297709 Ltd Bioventures Novartis 131 Front Street
Hamilton D0 HM12
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-17 1,498,791 $0.00 1,498,791 No 4 C Direct
Common Stock Acquisiton 2016-02-17 375,000 $8.00 1,873,791 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Redeemable Preferred Stock Disposition 2016-02-17 10,000,000 $0.00 1,318,932 $0.00
Common Stock Series B Convertible Redeemable Preferred Stock Disposition 2016-02-17 1,944,315 $0.00 179,859 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. This transaction represents the total number of shares of Common Stock of the Issuer (the "Issuer Common Stock") received upon the conversion of the Issuer's Series A Convertible Redeemable Preferred Stock (the "Series A Shares"), the payment of accrued dividends on the Series A Shares and the conversion of the Issuer's Series B Convertible Redeemable Preferred Stock (the "Series B Shares", collectively, the "Preferred Shares").
  2. These securities are held directly by Novartis Bioventures Ltd. ("Novartis Bioventures"). Novartis Bioventures is a corporation organized under the laws of Bermuda and is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG is a corporation organized under the laws of Switzerland and is the publicly owned parent of Novartis Bioventures Ltd.
  3. These securities were purchased in connection with the initial public offering of the Issuer.
  4. The Preferred Shares automatically converted into Issuer Common Stock on a 10.8102-to-1 basis upon the closing of the initial public offering of the Issuer without payment or further consideration. The Preferred Shares were convertible at any time at the election of the Reporting Person and had no expiration date.
  5. These securities include shares of Issuer Common Stock received as payment for accrued dividends on the Series A Shares.